Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

Samuel YamshonCaitlin GribbinMohammad AlhomoudNora ChokrZhengming ChenMichelle DemetresMichelle PasciollaJohn LeonardTsiporah ShorePeter Martin

Published in: Clinical lymphoma, myeloma & leukemia (2024)

Overall, this study serves as the first to delineate toxicity profiles associated with various available CAR T products. By better understanding associated toxicities, it may become possible to tailor therapies towards individual patients and anticipate the development of toxicities at earlier stages.

Keyphrases

cell therapy
end stage renal disease
oxidative stress
newly diagnosed
ejection fraction
chronic kidney disease
stem cells
peritoneal dialysis
patient reported